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Abstract:  
Background & Aims: Efficacy of bowel preparation is an important determinant of 
outcomes of colonoscopy. It is not clear whether approved low-volume polyethylene glycol 
(PEG) and non-PEG regimens are as effective as high-volume PEG regimens when taken in 
a split dose. 
 
Methods: In a systematic review of multiple electronic databases through January 31, 2019 
with a registered protocol (PROSPERO: CRD42019128067), we identified randomized 
controlled trials that compared low- vs high-volume bowel cleansing regimens, administered 
in a split dose, for colonoscopy. The primary efficacy outcome was rate of adequate bowel 
cleansing, and the secondary efficacy outcome was adenoma detection rate. Primary 
tolerability outcomes were compliance, tolerability, and willingness to repeat. We calculated 
relative risk (RR) and 95% CI values and assessed heterogeneity among studies by using the 
I2 statistic. The overall quality of evidence was asses ed using the GRADE framework. 
Results: In an analysis of data from 17 randomized controlled trials, comprising 7528 
patients, we found no significant differences in adequacy of bowel cleansing between the 
low- vs high-volume split-dose regimens (86.1% vs 87.4%; RR, 1.00; 95% CI, 0.98–1.02) 
and there was minimal heterogeneity (I2=17%). There was no significant difference in 
adenoma detection rate (RR, 0.96; 95% CI, 0.87–1.08) among 4 randomized controlled 
trials. Compared with high-volume, split-dose regimens, low-volume split-dose regimens 
had higher odds for compliance or completion (RR, 1.06; 95% CI, 1.02–1.10), tolerability 
(RR, 1.39; 95% CI, 1.12–1.74), and willingness to repeat bowel preparation (RR, 1.41; 95% 
CI, 1.20–1.66). The overall quality of evidence was moderate. 
Conclusions: Based on a systematic review of 17 randomized controlled trials, low-volume, 
split-dose regimens appear to be as effective as high-volume, split-dose regimens in bowel 
cleansing and are better tolerated, with superior compliance.  
 
KEY WORDS: endoscopy, comparative, adherence, screening 
 
Need to Know 
 
Background: It is not clear whether approved low-volume polyethylene glycol (PEG) and 
non-PEG regimens are as effective as high-volume PEG regimens when either are taken in a 
split dose. 
 
Findings: In a systematic review of 17 studies, we found split-dose, approved, low-volume 
regimens to be effective in bowel cleansing and more acceptable than high-volume 
regimens. 
 
Implications for patient care: Patients can effectively prepare for colonoscopy with split-




Adequate bowel cleansing is critical for detection f colorectal neoplasia and to 
minimize the risk of missed lesions and post-colonoscopy colorectal cancer (CRC) [1–3]. In 
addition, it improves colonoscopy efficiency, as inadequate cleansing has been associated 
with shorter surveillance intervals [4,5], longer procedure time [6] and need for early 
repetition of colonoscopy [7]. 
 
 Based on a favorable combination of high efficacy nd high safety [8–10], a split 
regimen of high-volume (3-4 liters, L) Polyethylene Glycol (PEG) regimen has become the 
reference standard for bowel preparation [11,12]. Suboptimal patient compliance and 
acceptability have been attributed to the large volume of bowel preparation to be 
administered, affecting patient experience and willingness to repeat the procedure [8,13]. 
Bowel preparation has been consistently rated as the worst phase of colonoscopy experience. 
  
 When considering patient experience as a relevant outcome of bowel preparation, 
low-volume PEG and non-PEG split regimens appear to be an attractive alternative, due to a 
substantial reduction in the volume to be administered, i.e. <2 L. Despite their hyper-
osmolarity, these low-volume regimens appear to be safe after exclusion of high-risk 
patients, i.e. those with renal or cardiovascular comorbidities [8,11–13]. 
 
 Thus, it is clinically relevant to assess whether low-volume split preparations are 
equally effective as high-volume split PEG regimens i  order to implement their use in 
clinical practice. Most of the previous meta-analyses did not show difference between split 
and non-split regimens, only partially addressing such an issue [13,14]. In addition, the only 
systematic review focusing on split-administration ncluded non-approved low-volume PEG 
regimens (i.e., Miralax-Gatorade) [8]. There is currently a paucity of data comparing high-
volume PEG and most of the low-volume, non-PEG regim ns. [8].  
 
 The primary aim of this systematic review and meta-an lysis is to assess whether 
low-volume PEG and non-PEG regimens are equally efficacious as high-volume PEG 
regimens, when administered in a split dose. 
  
METHODS 
The methods of our analysis and inclusion criteria were based on Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) recommendations [15]. Our 
systematic review protocol was registered with the Int rnational Prospective Register of 
Systematic Reviews (PROSPERO, www.crd.york.ac.uk/pros ero/) on March 2019 
(CRD42019128067). 
 
Data sources and search strategy 
A comprehensive electronic literature search was conducted in PubMed/MEDLINE, 
EMBASE and Scopus (up to January 31st 2019) to identify eligible studies comparing low 
and high volume bowel preparation before colonoscopy. PROSPERO was searched for 
ongoing or recently completed systematic reviews.References of the studies which were 
included were also manually searched for eligible articles. . Literature search was performed 
and verified by two authors (MS; GV). 
The search for studies of relevance was performed using the following text words and 
corresponding Medical Subject Heading/entrée (MeSH) terms when possible: “bowel 
preparation”, “low volume”, “split dose”, “split regimen”. The Medline search strategy was: 
“(((((low[All Fields] OR (low[All Fields] AND volume[All Fields])) OR (low[All Fields] 
AND dose[All Fields])) AND split[All Fields]) OR (split[All Fields] AND dose[All 
Fields])) OR (split[All Fields] AND ("clinical protocols"[MeSH Terms] OR ("clinical"[All 
Fields] AND "protocols"[All Fields]) OR "clinical protocols"[All Fields] OR "regimen"[All 
Fields]))) AND (("intestines"[MeSH Terms] OR "intestines"[All Fields] OR "bowel"[All 
Fields]) AND preparation[All Fields])”. 
 
Inclusion and exclusion criteria 
For the purpose of our meta-analysis, we screened all clinical studies published as full text 
paper or presented as an abstract at international meetings, for the following inclusion 
criteria:   
(I) Population: all adults undergoing elective colonoscopy, irrespective of the 
indication. 
(II)  Intervention: all low-volume bowel preparation regimens administered in split 
dose. 
(III)  Comparison: all high-volume PEG-based bowel preparation regimens 
administered in split dose.  
(IV)  Outcome: bowel preparation efficacy was recorded as the primary outcome. 
Secondary outcomes included compliance with the regim n, willingness to repeat 
the same bowel solution, palatability of the regimen, side effects. 
(V) Study design: only randomized controlled trials (RCTs) were considered.  
 
Exclusion criteria were as follows: 
(I) Essential information not available; 
(II)  Studies investigating bowel preparation regimen in special patients, such as 
pediatric patients, patients with a history of colorectal resection, inflammatory 
bowel disease patients or patients with a previous poor bowel preparation. 
(III)  Studies investigating bowel preparation regimens not approved and/or 
discouraged by European Guidelines (i.e., sodium phos ate). 
(IV)  Studies investigating bowel preparation regimens obtained by a non-approved 
combination of two products (e.g. Miralax-Gatorade). 
(V) Studies not reporting colon cleansing as a categorical parameter.  
 
Outcome assessment 
In our systematic review and meta-analysis, the primary outcome was the rate of patients 
with a successful bowel preparation in the 1) overall colon and 2) right colon. Considering 
the expected variation in outcomes nomenclature among the studies, we pre-defined a 
successful bowel preparation as a Boston Bowel Preparation Scale (BBPS)[16] score of ≥6, 
an Ottawa Bowel Preparation Score (OBPS)[17] of <5, an excellent or good bowel 
preparation reported by the endoscopists using the Aronchik Scale [18], or other non-
validated 3-, 4- or 5-point scales. A successful right colon preparation was defined as BBPS 
≥2 or an OBPS ≤2 in the right colon. Data on tolerability and side effects were extracted 
from the results of non-standardized questionnaires administered to the patients before 
colonoscopy: compliance with bowel preparation was defined as consumption of 75-100% 
of the prescribed solution, according to the cut-off adopted in the different series. Further, 
secondary outcomes were the proportion of patients willing to repeat the same bowel 
preparation and the rate of patients who reported a good/neutral palatability (tolerability) of 
the prescribed solution. Side effects such as abdominal bloating, nausea, vomiting, and 
abdominal pain/cramping were also reported. Other secondary outcomes were the rate of 
patients in whom at least an adenomatous lesion was detected (Adenoma Detection Rate, 
ADR), and the rate of patients with an excellent leve  of cleansing, when reported. We 
included withdrawals in the intention-to-treat (ITT) analysis. When both were presented, 
values from ITT were preferred to per-protocol (PP). 
 
Selection process 
Two review authors (MS; GV) independently screened the titles and abstracts. Full reports 
were obtained for all titles that appeared to meet th  inclusion criteria or where there was 
any uncertainty and they were screened based on the selection criteria. Any disagreement 
was resolved by consensus with the senior author (CH). The reasons for excluding trials 
were recorded. Neither of the review authors were blinded to the journal titles or to the study 
authors or institutions. When there were multiple articles from a single institute, we used the 
latest publication from that institute. 
 
Data extraction 
Using standardized forms, two reviewers (MS, GV) extracted data independently. Any 
disagreements were resolved by discussion with two senior authors (CH and AR). The 
following data were extracted for each study: first au hor, year of publication, study design, 
number of endoscopy centers, country, number of patients, withdrawals, patients with an 
adequate level of cleansing, patients with an excellent level of cleansing, compliance, 
willingness to repeat, palatability, side effects (abdominal pain, bloating, nausea, vomiting, 




As the outcomes were dichotomous events, the measure of effect of interest were pooled 
proportions and risk ratios (RR) along with 95 % confidence interval (95 % CI). P-value < 
0.05 was considered statistically significant. A random effects model described by 
DerSimion and Laird was used for calculating pooled rates. Heterogeneity among studies 
was assessed by calculating the I2 measure of inconsistency. An I2-value of 0-30%, 30-60%, 
50-90% and 75-100% was indicated as low, moderate, substantial and considerable 
heterogeneity, respectively.  Publication bias was assessed by funnel plot with trim-and-fill 
methodology and by Egger’s regression test. Sensitivity analysis was performed for the most 
clinically relevant variables. Statistical analyses were conducted with metafor package  for R 
[19,20]. Heterogeneity was investigated through subgroup analyses according to country, 
type of study (i.e. single or multicenter) and type of bowel preparation, along with meta-
regression including the following variables: country, publication year, type of bowel 




Study quality was assessed by the Cochrane risk bias tool for randomized studies. Two 
reviewers (MS, GV) assessed quality measures for included studies and discrepancies were 
adjudicated by collegial discussion. We appraised the overall quality of evidence by 
applying GRADE methodology for the primary outcome[21]. 
 
RESULTS 
Study characteristics and quality 
The literature search resulted in 727 articles (Figure 1). After reviewing the title and 
abstract, 24 articles were retrieved as full text. Of these, 17 articles fulfilled the inclusion 
criteria and were finally included in the systematic review [22–39].  
 
Studies characteristics are briefly reported in Table 1. All studies were published 
between 2008 and 2019. Six studies were performed in Italy (4,928 patients), 5 studies 
(1,015 patients) in Korea, 4 studies(767 patients) i  Netherlands, and the remaining studies 
in Czech Republic (259 patients), Germany (359 patients) and Lebanon (200 patients), 
respectively. Eleven studies involved multiple centers, while 7 studies were single-center 
experiences.  
 
Regarding bowel preparation scales, the Aronchick scale was used in 5 studies, the 
Ottawa bowel preparation scale in 4 studies, the Boston bowel preparation scale in 4 studies, 
and non-validated scales were used in 8 studies. 
 
Altogether, the 17 studies included 7,528 patients i  the intention-to-treat analysis, 
3,749 being in the low-volume split group and 3,779 in the high-volume split group. 
Baseline characteristics in terms of age and gender were comparable between the two 
groups. Risk of bias was low for all except for allocation concealment (i.e. blinding of 
endoscopists at randomization) and incomplete outcome data (i.e., for excluded patients) 
(Appendix 1). Reasons to remain included at PP analysis are explainedin Appendix 2. 
 
Regarding the type of low-volume regimen, 2L-PEG with ascorbic acid as adjuvant 
(PEG-A) was the low-volume preparation adopted in 9 studies, a combination of 2L-PEG 
with citrate and simethicone (PEG-C) in 4 studies (with the addition of bysacodil in 2), 
sodium picosulfate with magnesium citrate (SPMC) in 3 studies, and oral sulfate solution 
(OSS) in 2 studies. 
 
Primary outcome: Efficacy (overall and right colon)  
          Low-volume PEG and non-PEG regimens vs. high-volume regimen in split dose  
Based on the data reported by all the 17 studies (7,528 patients, 36 arms of 
treatment), low-volume split bowel regimens had an equivalent proportion of patients with 
an adequate bowel preparation compared with split-dose high-volume PEG [ 86.1% (95%CI 
82.6-90%) vs. 87.4% (95%CI 84.1-90.7%)]. The pooled RR was 1.00 (95% CI 0.98-1.02; 
I2= 17%; p= 0.2) showing no statistically significant difference with low heterogeneity 
(Figure 2) (Table 2).  
In the studies reporting data on right colon (10 studies, 5,288 patients), there was no 
difference in efficacy between low-(PEG and non-PEG) volume and high-volume PEG 
regimens [91.2% (95%CI 89.1-93.3%) vs. 89.6% (95%CI 87.3-92%)] with a RR of 
1.01(95% CI 0.99-1.03; I2= 18%; p=0.22) (Figure 3) (Table 2).  
Publication bias was assessed using Funnel plots and Egger’s test (p=0.13 and 
p=0.06) for both the primary outcomes (Appendix 3). According to trim-and-fill, no 
significant difference between the included studies, with or without trimmed studies, was 
found for primary outcome. 
 
Low-volume PEG 
Split-dose 2L-PEG with the adjuvant of ascorbic or cit ic acid had a comparable 
proportion of patients with an adequate bowel preparation compared with high-volume split 
PEG [13 studies: 6,593 patients; 84.9% (95%CI 80.8-89%) vs. 86.3% (95%CI 82-90.5%)] 
with a  RR of 1.00(95% CI: 0.96-1.02; I2= 38%; p=0.09) Table 2]. For those studies 
reporting data on right colon cleansing (7 studies: 4,805), no difference in efficacy between 
low- and high-volume PEG was found [90.5% (95%CI 87.3-93.6%) vs. 88.4% (95%CI 85-
91.9%)] with a RR of 1.01(95% CI: 0.98-1.04; I2= 48%; p=0.07) (Table 2). There was no 
significant publication bias (Egger’s test: p=0.18 and p=0.32) for the two end-points.  
Separate analysis for PEG-A and PEG-C is reported in Table 2 and Appendix 4. 
 
Low-volume non-PEG 
As shown in Table 2, split-dose non-PEG regimens had a comparable proporti n of 
patients with an adequate bowel preparation compared with high-volume split PEG [5 
studies: 935 patients; 89.5% (95%CI 83.6-95.4%) vs. 91% (95%CI 87.8-94.2%)] with a RR 
of 1.00 (95%CI: 0.96-1.04; I2= 0%; p=0.72).  
For those studies reporting data on right colon cleansing, no difference in efficacy 
between low-volume non-PEG and high-volume PEG regim ns was found [3 studies: 483 
patients; 92.2% (95%CI 88.8-95.6%) vs91.4% (95%CI 87.9-94.9%)] with an RR of 
1.01(95% CI: 0.96-1.06; I2= 0%; p=0.99) (Table 2). No significant publication bias was 
seen (Egger’s test: p=0.32 and p=0.90) for the two end-points.  
Separate analysis for SPMC and OSS is reported in Table 2 and Appendix 4. 
 
Secondary outcomes: Patient experience (Table 3) 
Compliance 
In 13 studies (6,570 patients) assessing compliance to bowel preparation, patients 
receiving low-volume PEG and non-PEG regimens were more likely to complete the 
preparation than those receiving high-volume volume pr paration [92.8% (95%CI 89.6-
96.1%) vs. 86.8% (95%CI 82.1-91.4%)] with a RR of 1.06(95% CI: 1.02-1.10; I2= 85%; 
p<0.01). Separate analysis for PEG and non-PEG low-volume regimens are provided in 
Table 3 (Forest Plot in Appendix 5). 
 
Tolerability 
In 9 studies (5,364 patients) assessing tolerability (i.e. palatability/acceptability) of 
bowel preparation, the low-volume PEG and non-PEG group demonstrated statistically 
significantly higher tolerability as compared with the high-volume group [ 72.5% (95%CI 
56.4-88.7%) vs. 49.6% (95%CI 28.8-70.5%)] with a RR of 1.39[95% CI: 1.12-.74; I2= 
98%; p<0.001)]. Separate analysis for PEG and non-PEG low-volume regimens are 
provided in Table 3 (Forest Plot in Appendix 6). 
 
Willingness to repeat the same preparation 
In the 4 studies (815 patients) assessing the willingness to repeat the same bowel 
preparation regimen, there was a significant difference in favour of low-dose PEG and non-
PEG regimens as compared to high-volume PEG [89.5% (95%CI 80.3-98.7%) vs. 61.9% 
(95%CI 47.8-76.1%)] with a RR of 1.41[95% CI: 1.20-1.66; I2= 71%; p<0.001)]. Separate 
analysis for PEG and non-PEG low-volume regimens are provided in Table 3 (Forest Plot 
in Appendix 7). 
 
Adverse events, adenoma detection rate and sensitivity analysis 
Data on adverse events for each study, ADR, and sensitivity analysis (per protocol analysis, 
validated scales, exclusion of BBPS, year of publication) are summarized in Appendix 8 
and 9, respectively. There was no significant difference in adenoma detection rate between 
low- and high-volume regimens (RR: 0.96; 95% CI 0.87, 1.08). 
No variable was found to significantly influence the pooled estimates for the primary 
outcome in the meta-regression analysis (Appendix 10). Compliance to low-volume bowel 
preparation was significantly worse in multicenter studies (p = 0.013) (Appendix 11). 
Tolerability to low-volume bowel preparation was significantly increased among studies 
using SPMC (p=0.004), whereas it was inversely related to the percentage of CRC screening 
patients (Appendix 12). Willingness to repeat low-volume bowel preparation was 
significantly increased in studies using PEG-A than in PEG-CS ones (p=0.003), and among 
older patients (Appendix 13). Subgroup analyses according to country, type of study (i.e. 
mono or multicenter) and type of preparation according to adjuvants were consistent with 




The quality of evidence was assessed by applying GRADE methodology. Overall, moderate 
quality of evidence shows that split-dose low-volume bowel preparations are equally 
effective as high-volume regimens. The level of evid nce for RCTs was downgraded due to 
inconsistency owing to heterogeneity among patients (i.e. different indications to 






According to our meta-analysis, both low- and high-volume preparations used in 
split dose are equally effective in cleansing the ov rall colon and  the right colon. The 
equivalence in efficacy was independent of the type of preparations – i.e. PEG or non-
PEGlow-volume regimens, as all the individual prepaations analyzed showed a similar 
pattern of efficacy. In addition, our analysis confirms a better patient experience, especially 
in terms of willingness to repeat the same preparation, with a low-volume regimen. 
 
Our analysis shows that the low-volume PEG and non-PEG regimens are 
comparative to high-volume PEG regimen which is different whencompared to the previous 
meta-analysis showing superiority in efficacy of a high-volume PEG over a low-volume 
PEG regimen used in a split dose [8].  First, by including 7 more low-volume PEG and 3 
additional non-PEG RCTs  compared to the previous meta-analysis,we increased the number 
of patients by 7-fold and 2-fold respectively. This also allowed us to make statistically 
meaningful comparison between each individual non-PEG regimen and a high-volume 
regimen, as only one RCT for each regimen was availble in the previous review [8]. 
Secondly, we excluded non-approved regimens of low-v lume PEG preparations, such as 
those based on the combination between PEG and Gatorade, as well as those preparations 
which are discouraged, such as sodium phosphate. Both of these factors attenuated 
thesuperiority shown for high-volume PEG split regimens. Although similar results have 
been shown in a previous meta-analysis [13], the equivalence we showed between low- and 
high-volume regimens was restricted to studies adopting a split regimen which makes it 
different from the previous meta-analysis by Xie et al. As non-split dose series represent a 
mere confounder [11,12], our analysis with only split dose regimens is more clinically 
meaningful setting for decision-making process. Third, we did not limit the efficacy of 
cleansing in the overall colon [8,13], but we also sh wed the equivalence between low- and 
high-volume regimens in the right colon. This is clini ally relevant, as both adenomatous 
and serrated lesions tend to be more frequently flat and subtle in the proximal colon, 
requiring good preparation of the right colon. 
 
The better patient experience achieved by low-volume regimens is also clinically 
relevant. Low-volume regimens were superior in each individual end-point we selected for 
patient experience, with a similar trend for most of he adverse events related with bowel 
preparation. When coupling the equivalent efficacy with a better experience, there is 
compelling evidence to recommend a low-volume split regimen as alternative to the high-
volume regimen, unless additional factors, such as cost or patient preferences, supports a 
different choice. Of note, the advantage of the low-volume group in terms of willingness to 
repeat bowel preparation was significantly increased when considering PEG-A vs. PEG-CS 
studies, suggesting a possible role of the adjuvants. The consistency of the study results 
across regimens with different mechanism of action – such as PEG and non-PEG agents, is 
unclear. This may be related tothe timing of administration – i.e. split vs. non-split, rather 
than just theaction of the hyperosmolar product. Thus t e efficacy of the split-dose regimens 
could be related to both the timing of administration and also the laxative properties of the 
different regimens. Of note, we also excluded that e main mechanism of efficacy of low-
volume regimens is a higher compliance to low- versus high-volume for two reasons. First, 
the equivalence between low- and high-volume was nerly the same when passing from ITT 
to PP analysis, despite the main difference between ITT and PP is represented by the cut-off 
in the amount of product actually taken; secondly, the difference between low- and high-
volume regimens in terms of compliance was limited to 6%. 
 
The strength of our analysis is not only because of the large number of patients , but 
also thelow heterogeneity found in most of the comparisons on primary outcomes, as well as 
by its robustness in any of the sensitivity analysis applied. This is to be related to the fact 
that the operators in such studies are fully blinded to the product used, while the fact that 
patients were not blinded may have affected the secondary rather than primary outcomes. 
 
The main limitation of our analysis is that an intri sic selection bias in high-quality 
randomized trials – i.e. the exclusion of patients with major comorbidities, which limits the 
assessment of safety of the hyperosmolar low-volume regimens. Thus, caution is required 
when prescribing these agents to frail or severely-ill patients, whereas the isotonic high-
volume regimens may be a safer choice. The same selection bias may apply to inpatients, 
patients with prior failed preps, those with prior resections, severe constipation or treated 
with opiates. We included studies using the Boston Bowel Preparation Scale that is 
somewhat suboptimal for assessing the efficacy of pr ducts as it is influenced by washing 
the colon during the procedure. However, only 4 studies actually used this scale, and the 
results were unchanged when these studies were exclud d in sensitivity analysis. Adjuvants 
to bowel preparation may play a role in the efficacy of colon cleansing therefore acting as 
confounders [40]. However, subgroup analyses on PEG-A and PEG-C confirmed similar 
efficacy rates. A concern regarding all the meta-anlyses, including ours,on bowel 
preparation, is about the primary outcome being not homogeneously reported across the 
included studies because of the different scales usd. However, we corroborated our findings 
through subgroup analysis pooling data of studies which used comparable definitions for 
bowel preparation and cleanliness.  
 
In conclusion, our analysis shows the equivalence between low- and high-volume 
regimens, when a split dose administration is adopted. The better patient experience 
associated with such low-volume regimens indicates th ir potential as first-choice agents. 
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Ell 2008 [23] Germany 14 PEG-A 180 179 59 (18–
88)1 


































1 PEG-A 62 73 NA2 NA2 Various2 Outpatien
ts: 100% 


















































Moon 2014 Korea 3 PEG-A 181 180 52.3 50.2%1  Various; Outpatien $ NA NA NV 159 162 
[28] (11.8) & 
54.0 
(11.6)1,3 








1 SPMC 85 88 55.26 




































































































































Italy 6 PEG-C 45 46 NA2 NA2 NA2 Outpatien
ts: 100% 







Korea 9 OSS 97 96 68.6 ± 2.9 


















1available for Per-Protocol population, 2available for the main cohort, 3separately available for the 2 arms 
$: Severe systemic comorbidities excluded, consistent with contraindications of bowel preparations. 
NA: Not Available 
AS: Aronchick Scale, BBPS: Boston Bowel Preparation Scale, I/O: Inpatient/Outpatient, ITT: intention-to-treat, NV: Non-validated scale, OBPS: Ottawa Bowel Preparation Score, 
OSS: Oral Sulfate Solution, PEG-A: Polyethylene Glyco  plus Ascorbic Acid, PEG-C: Polyethylene Glycol-itrate, SPMC: Sodium picosulfate with magnesium citrate, 

Table 2. Primary outcome in terms of efficacy of cleansing for the overall colon and right 
colon according to low-volume PEG and non-PEG split regimens as compared with high-






(ITT, n)  
Relative Risk 
(95% CI)  
All colon 
I 2 N° of 
trials 
Patients 
(ITT, n)  
Relative Risk  
(95% CI)  
Right colon 
I 2 
Efficacy all colon Efficacy right-colon 
PEG &  
non-PEG 
18 7,528 1.00 [0.98, 1.02] 17% 10 5,288 1.01 [0.99-1.03] 18% 
    - PEG 13 6,593 1.00 [0.96, 1.02] 38% 7 4,805 1.01 [0.98-1.04] 48% 
         -PEG-A 9 3,962 0.98 [0.94, 1.02] 40% 5 2,647 1.02 [0.99, 1.04] 1% 
         -PEG-C 4 2,631 1.02 [0.96, 1.08] 48% 2 2,158 1.04 [0.93-1.15] 80% 
   - non-PEG 5 935 1.00 [0.96-1.04] 0% 3 483 1.01 [0.96-1.06] 0% 
         -SPMC 3 532 0.98 [0.92-1.04] 0% 2 273 1.01 [0.94-1.08] 0% 
         -OSS 2 403 1.01 [0.96-1.06] 0% 1 210 1.01 [0.93-1.09] NA 
 
  
Table 3. Secondary outcomes in terms of patient experience. CI: Confidence Interval. 
Secondary end-point Number 
of trials 
Patients 
(ITT, n)  





  -PEG & non-PEG 13 6,570 1.06 [1.02-1.10] 85% 
       -PEG 9 5,808 1.08 [1.03-1.14] 86% 
       -non-PEG 4 762 1.01 [0.98-1.04] 16% 
Tolerability 
  -PEG & non-PEG 9 5,364 1.39 [1.12-1.74] 98% 
      -PEG 5 4,566 0.92 [0.85, 0.99] 84% 
      -non-PEG 4 742 0.51 [0.27, 0.95] 96% 
Willingness to repeat 
  -PEG & non-PEG 4 815 1.41 [1.20-1.66] 71% 
      -PEG 3 622 1.46 [1.15-1.86] 74% 
      -non-PEG 1 193 1.37 [1.18-1.59] NA 
 
    
 
  
Figure 1. Study flow-chart. 
Figure 2. Forest plot for the primary outcome (rate of adequate level of bowel preparation in 
the overall colon) according to the low-volume PEG and non-PEG regimen adopted in the 
included studies. 
Figure 3. Forest plot for the primary outcome (rate of adequate level of bowel preparation in 
the right colon) according to the low-volume PEG and non-PEG regimen adopted in the 
included studies.  
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Parente low Unclear low low low low Low 
Zorzi low Unclear low low low low low 
Valiante low High low low high low high 
Moon low Unclear low unclear high low low 
Sharara low Unclear low low unclear low low 
Marmo low Low low low low low high 
Jansen low Unclear low low low low low 
Jung low Unclear low low low low low 
Mathus-
Vliengen 
high High high low low unclear Unclear 
(comorbidities 
not reported) 
Ell low Low unclear low high low Low 
Musterma
n 
low Low high low low low Unclear 
(comorbidities 
not reported) 
Kojecky unclear Low unclear low high unclear High (imbalance 
in diabetes 
prevalence)  
Kim unclear Unclear low low unclear unclear Unclear 
(demographics 
not reported) 
Corporaal high High low high high low Unclear 
(demographics 
not reported) 
Spada low Low low low low low low 
Kwak low Low unclear unclear high low low 
Yang low Low low low low low low 
 
Other bias included: demographic imbalance, imbalanced indication to colonoscopy, 












Appendix 2. Reasons to pass from ITT to PP analysis. 
Reference Criteria to exclude from the PP analysis 
  
Ell 2008 
Participants ingesting < 75% of study medication;  Colonoscopy not taken;  
assessment by expert panel 
Marmo 2010 \ 
Corporaal 2010 \ 
Jansen 2011 \ 
Valiante 2013 Colonoscopy not taken; patients not repo ting the bowel preparation taken. 
Mathus-Vliengen 2013 \ 
Moon 2014 \ 
Musterman 2014 Patients taking different bowel prepa ation. 
Kojecky 2014 \ 
Kim 2014 \ 
Parente 2015 \ 
Zorzi 2015 
Patients taking different bowel preparation; not reporting the bowel preparation 
taken. 
Zorzi 2015 
Patients taking different bowel preparation; not reporting the bowel preparation 
taken. 
Sharara 2015 \ 
Jung 2016 
Withdrawal of consent; Colonoscopy not taken; Failure of cecal intubatioin; 
prior colorectal surgery 
Yang 2016 
Participants ingesting < 75% of study medication or ot completing 
colonoscopy 
Spada 2017 \ 

















Appendix 3. Funnel plots for assessing publication bias. 
1) Primary outcome: overall colon (left) and right colon (right). 
 
          
 
2) Secondary outcome: compliance (left), tolerability (centre), willingness to repeat (right) 
 
Appendix 4. Further details on primary outcomes for specific low-volume PEG and non-
PEG products. 
2 L-PEG + Ascorbic Acid (PEG-A) 
Split-dose 2L-PEG with the adjuvant of ascorbic acid had a comparable proportion of 
patients with an adequate bowel preparation compared with high-volume split PEG (9 
studies: 3,962 patients; 1,711/1,969, 83.5% (95%CI 78.1-88.8%) vs. 1,742/1,993, 86.6% 
(95%CI 81-92.3%); RR: 1.00; 95% CI, 0.97, 1.02; I2= 48%; p= 0.74). The moderate 
heterogeneity was purely attributed to one series weighting for 26% of the overall 
population. For the right colon cleansing level (5 studies: 2,647 patients; 1,030/1,310, 89.3% 
(95%CI 84.1-94.6%) vs. 1,046/1,337, 88.4% (95%CI 84.3-92.4%); RR: 1.00; 95% CI: 0.97-
1.05; I2= 44%; p= 0.89). When excluding one series, [27] no residual heterogeneity was 
found (I2= 0%). 
 
2L-PEG -citrate (PEG-C) 
No statistically significant difference was shown between split-dose low volume PEG-C and 
split-dose high-volume PEG. The pooled RR was 0.99 (4 studies: 2,631 patients; 
1,183/1,318, 87.8% (95%CI 82-93.6%) vs. 1,175/1,313, 85.5% (95%CI 79.3-91.7%); RR: 
0.99; 95% CI: 0.96-1.02; I2= 38%; p= 0.48). When excluding one series, [29] no residual 
heterogeneity was found (I2= 0%). For the right colon cleansing level (2 studies: 2,158 
patients; 859/1,080, 82.1% (95%CI 74.3-89.8%) vs. 838/1,078, 77.8% (95%CI 75.3-80.3%); 
RR: 1.02; 95% CI: 0.98-1.07; I2= 0%; p= 0.23).  
 
Sodium picosulfate with magnesium citrate (SPMC) 
In the 3 trials (532 patients) reporting data on SPMC, the proportion of patients with 
adequate cleansing was similar between SPMC and high-volume PEG (221/260, 85.6% 
(95%CI 77.1-94%) vs. 240/272, 88.8% (95%CI 84.6-92.3%); RR: 0.96; 95% CI 0.90-1.03; 
I2= 0%; p=0.30). 
 
Oral Sulfate Solution (OSS) 
In the 2 trials (403 patients) reporting data on OSS, the proportion of patients with adequate 
cleansing was similar between OSS and high-volume PEG (190/202, 94.5% (95%CI 91.2-
97.9%) vs. 187/201, 93.4% (95%CI 90-96.8%); RR: 1.01; 95% CI 0.93-1.09; I2= 0%; 
p=0.68).  
  
Figure. Forest plot according to the individual low-volume PEG and non-PEG regimen. 
 
  
Appendix 5. Forest plot for the secondary outcome: Compliance. 
 
  
Appendix 6. Forest plot for the secondary outcome: Tolerability. 
 
  




Appendix 8. Adverse events, adenoma detection rate and rate of excellent cleansing in the 
low- and high-volume split regimens. For adverse evnts, RR <1 indicates lower risk in the 
low-volume group. For adenoma detection and excellent evel of cleansing RR ≥1 favours 
low-volume regimens. 





(95% CI)  
All colon 
I2 
Abdominal pain 8 1820 1.22 [0.73-2.03] 54% 
Bloating 6 918 0.66 [0.48-0.92] 48% 
Nausea 8 1198 0.86 [0.72-1.02] 50% 
Vomiting 7 1529 0.68 [0.46-1.00] 4% 
Sleep disorders 4 822 0.67 [0.39-1.15] 0% 
Adenoma detection rate 4 5,399 0.96 [0.87, 1.08] 0% 
Rate of excellent level of 
cleansing 
7 6,281 0.94 [0.86, 1.02] 21% 
  
Appendix 9. Sensitivity analysis for the primary outcome (rate of adequate bowel 
preparation for overall colon). 





(95% CI)  
All colon 
I2 
EFFICACY Per Protocol 
Low-volume PEG & non-PEG 18 7,399 0.99 [0.98, 1.01] 22% 
   -Low-volume PEG 13 6476 0.99 [0.97, 1.01] 38% 
         -PEG-A 9 3861 0.98 [0.94, 1.01] 59% 
          -PEG-C 4 2615 1.00 [0.98, 1.02] 0% 
   -Low-volume non-PEG 5 923 1.00 [0.97, 1.04] 0% 
          -SPMC 3 531 0.97 [0.91, 1.04] 0% 
          -OSS 2 392 1.02 [0.98, 1.06] 0% 
EFFICACY only validated scales 
Low-volume PEG & non-PEG 13 6,023 1.00 [0.98, 1.02] 10% 
   -Low-volume PEG 8 5,088 1.00 [0.97, 1.02] 23% 
         -PEG-A 5 2,737 0.98 [0.92, 1.04] 50% 
          -PEG-C 3 2,351 0.99 [0.97, 1.02] 0% 
   -Low-volume non-PEG 5 935 1.00 [0.96, 1.04] 0% 
          -SPMC 3 532 0.98 [0.92-1.04] 0% 
          -OSS 2 403 1.01 [0.96-1.06] 0% 
EFFICACY (studies >2014) 
Low-volume PEG & non-PEG 12 5,794 1.00 [0.98, 1.02] 10% 
   -Low-volume PEG 7 4,859 1.00 [0.97, 1.02] 25% 
         -PEG-A 4 2,549 0.98 [0.92-1.04] 52% 
          -PEG-C 3 2,320 0.99 [0.97-1.03] 0% 
   -Low-volume non-PEG 5 935 1.00 [0.96-1.04] 0% 
          -SPMC 3 532 0.98 [0.92-1.04] 0% 
          -OSS 2 403 1.01 [0.96-1.06] 0% 
 
 
Appendix 10. Metaregression analysis for bowel cleansing efficacy. 
 Coefficient Standard Error P value R2 
Publication year 0.005 0.004 0.253 27% 
Country (Europe vs. Asia) 0.015 0.024 0.516 0% 
Multicenter study (vs. monocenter) 0.012 0.023 0.62 0% 
Bowel preparation scale    0% 
    Not validated (reference) - - -  
    Aronchick -0.001 0.030 0.968  
    BBPS 0.016 0.034 0.633  
    OBPS 0.007 0.041 0.856  
Type of preparation    0% 
    PEG-A (reference) - - -  
    PEG-CS 0.069 0.096 0.475  
    OSS 0.032 0.038 0.405  
    SPMC -0.006 0.041 0.884  
Type of preparation (PEG vs. non-
PEG) 
-0.001 0.025 0.976 0% 
Indication to colonoscopy (% of 
CRC screening patients) 
0.001 0.001 0.151 0% 
Constipation % -0.001 0.001 0.834 0% 
Mean age in low-volume group 0.003 0.002 0.261 0% 
Mean age in high-volume group 0.001 0.002 0.793 0% 
Male sex % in low-volume group -0.032 0.086 0.713 0% 
Male sex % in high-volume group 0.050 0.124 0.686 0% 
 
  
Appendix 11. Metaregression analysis for compliance to the bowel preparation. 
 Coefficient Standard Error P value R2 
Publication year -0.005 0.008 0.548 0% 
Country (Europe vs. Asia) 0.019 0.040 0.637 0% 
Multicenter study (vs. monocenter) -0.087 0.035 0.013 50% 
Type of preparation    0% 
    PEG-A (reference) - - -  
    PEG-CS 0.046 0.048 0.345  
    OSS -0.047 0.054 0.389  
    SPMC -0.045 0.062 0.465  
Type of preparation (PEG vs. non-
PEG) 
0.061 0.040 0.125 3% 
Indication to colonoscopy (% of 
CRC screening patients) 
0.001 0.001 0.440 0% 
Constipation % -0.001 0.001 0.834 0% 
Mean age in low-volume group 0.001 0.004 0.851 0% 
Mean age in high-volume group -0.002 0.005 0.635 0% 
Male sex % in low-volume group -0.005 0.116 0.968 0% 
Male sex % in high-volume group 0.027 0.193 0.890 0% 
 
Appendix 12. Metaregression analysis for tolerability of the bowel preparation. 
 Coefficient Standard Error P value R2 
Publication year -0.075 0.080 0.345 4% 
Country (Europe vs. Asia) -0.002 0.251 0.993 0% 
Multicenter study (vs. monocenter) -0.399 0.255 0.117 14% 
Type of preparation    62% 
    PEG-A (reference) - - -  
    PEG-CS -0.168 0.216 0.575  
    OSS -0.126 0.224 0.437  
    SPMC 0.550 0.190 0.004  
Type of preparation (PEG vs. non-
PEG) 
-0.361 0.213 0.090 16% 
Indication to colonoscopy (% of 
CRC screening patients) 
-0.007 0.002 0.001 82% 
Constipation % -0.001 0.001 0.215 0% 
Mean age in low-volume group -0.001 0.022 0.658 0% 
Mean age in high-volume group -0.004 0.022 0.850 0% 
Male sex % in low-volume group -0.942 1.529 0.538 0% 
Male sex % in high-volume group -2.046 1.744 0.241 12% 
 
 
Appendix 13. Metaregression analysis for willingness to repeat the bowel preparation. 
 Coefficient Standard Error P value R2 
Publication year -0.023 0.046 0.614 0% 
Country (Europe vs. Asia) -0.042 0.201 0.834 0% 
Multicenter study (vs. monocenter) -0.279 0.180 0.123 54% 
Type of preparation    99% 
    PEG-A (reference) - - -  
    PEG-CS -0.325 0.109 0.003  
    OSS -0.204 0.126 0.104  
Type of preparation (PEG vs. non-
PEG) 
0.063 0.232 0.785 0% 
Indication to colonoscopy (% of 
CRC screening patients) 
-0.006 0.004 0.116 99% 
Constipation % -0.001 0.001 0.834 0% 
Mean age in low-volume group 0.017 0.008 0.042 99% 
Mean age in high-volume group 0.016 0.008 0.040 99% 
Male sex % in low-volume group 0.303 0.258 0.240 29% 
Male sex % in high-volume group 0.691 0.363 0.057 76% 
 
  
Appendix 14. Subgroup analyses for bowel cleansing efficacy. 
Subgroup 
analysis 
Number of trials Patients RR (95%CI) I2 
EFFICACY all colon 
Country     
    Europe 12 6,313 1.00 (0.98-1.02) 29% 
    Asia 6 1,215 0.99 (0.95-1.02) 0% 
Type of study     
    Monocenter 7 1,347 0.98 (0.93-1.04) 51% 
    Multicenter 11 6,181 1.00 (0.98-1.02) 11% 
Scale for bowel 
cleansing 
evaluation 
    
    Aronchick 5 4,299 0.98 (0.94-1.03) 64% 
    BBPS 4 727 1.01 (0.97-1.05) 0% 
    OBPS 4 997 1.00 (0.94-1.06) 0% 
    Not validated 5 1,505 0.99 (0.93-1.05) 57% 
EFFICACY right colon 
Country     
    Europe 6 4,417 1.00 (0.97-1.03) 51% 
    Asia 4 871 0.97 (0.93-1.02) 0% 
Type of study     
    Monocenter 6 977 0.98 (0.91-1.04) 58% 
    Multicenter 4 4,311 1.00 (0.98-1.03) 27% 
Scale for bowel 
cleansing 
evaluation 
    
    Aronchick 4 4,040 1.00 (0.96-1.03) 53% 
    BBPS 2 383 1.01 (0.95-1.07) 0% 
    OBPS 1 89 0.92 (0.82-1.05) NA 
    Not validated 3 776 1.00 (0.92-1.09) 73% 
NA, not applicable. 
  
Appendix 15. Subgroup analyses for secondary outcomes. 
Subgroup 
analysis 
Number of trials Patients RR (95%CI) I2 
COMPLIANCE  
Country     
    Europe 8 5,555 1.07 (1.01-1.13) 90% 
    Asia 5 1,015 1.04 (0.99-1.09) 46% 
Type of study     
    Monocenter 4 839 1.13 (1.06-1.20) 43% 
    Multicenter 9 5,731 1.03 (1.00-1.07) 79% 
Type of 
preparation 
    
    PEG-A 6 3,268 1.06 (1.01-1.11) 75% 
    PEG-CS 3 2,540 1.12 (1.01-1.25) 87% 
    OSS 2 403 1.00 (0.98-1.02) 0% 
    SPMC 2 359 1.02 (0.92-1.13) 51% 
TOLERABILITY 
Country     
    Europe 5 4,542 1.40 (1.01-1.90) 99% 
    Asia 4 822 1.35 (1.02-1.77) 71% 
Type of study     
    Monocenter 3 643 3.62 (0.57-22.9) 97% 
    Multicenter 6 4,721 1.27 (1.03-1.57) 99% 
Type of 
preparation 
    
    PEG-A 4 2,744 1.25 (0.99-1.57) 76% 
    PEG-CS 1 1,878 1.05 (1.02-1.08) NA 
    OSS 1 210 1.09 (0.97-1.23) 0% 




WILLINGNESS TO REPEAT BOWEL PREPARATION 
Country     
    Europe 2 471 1.43 (1.00-2.04) 84% 
    Asia 2 344 1.42 (1.24-1.62) 0% 
Type of study     
    Monocenter 1 89 1.75 (1.34-2.31) NA 
    Multicenter 3 726 1.33 (1.16-1.52 58% 
Type of 
preparation 
    
    PEG-A 2 240 1.68 (1.38-2.04) 0% 
    PEG-CS 1 382 1.21 (1.11-1.32 NA 
    OSS 1 193 1.37 (1.18-1.59) NA 
    SPMC 0 0 NA NA 
NA, not applicable.  
Appendix 16. GRADE evidence profile for efficacy of split-dose low- vs. high-volume bowel 
preparations for colonoscopy. 
 
* Inconsistency risk was judged as serious due to he erogeneity among patients (i.e. different 
indications to colonoscopy) and scales for bowel clansing evaluation. 




 Quality assessment Summary of findings Quality 
Outcome, 
No. of studies, 
design  
(no. of patients) 
Risk 
of bias 
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